Home / Clinical areas / Pharmacogenetics

Pharmacogenetics

  • Pharmacogenetics global panel [30 genes]    (all clinical areas included)

    Ref.: S-202212590|Turnaround time (TAT) 25 days

  • Pharmacogenetics service for a clinical area (single clinical area)

    Ref.: S-202212575|Turnaround time (TAT) 25 days

    • Central nervous system
    • Digestive system and metabolism
    • Analgesics, anesthetics and musculoskeletal system
    • Cardiovascular system
    • Immunosuppressive agents
    • Respiratory system
    • Antineoplastic agents
    • Anti-infective agents
    • Genitourinary system and sex hormones
    • Dermatology
    • Antidotes
  • Clozapine Pharmacogenetics [10 genes]

    Ref.: S-202110203|Turnaround time (TAT) 10 days

  • Pharmacogenetics of lipid-lowering agents [6 genes]

    Ref.: S-201907369|Turnaround time (TAT) 25 days

  • Antiplatelet and anticoagulation pharmacogenetics [13 genes]

    Ref.: S-202008274|Turnaround time (TAT) 25 days

  • Dihydropyrimidine dehydrogenase deficiency (5-fluorouracil toxicity). Sequencing of DPYD gene
    [1 gene]

    Ref.: S-202212057|Turnaround time (TAT) 25 days

Genotyping services

  • Pharmacogenetics DPYD genotyping 4 variants

    Ref.: S-202110029|Turnaround time (TAT) 5 days

  • Pharmacogenetics CYP2C9 genotyping 2 variants

    Ref.: S-202110395|Turnaround time (TAT) 10 days

  • Pharmacogenetics CYP2C19 genotyping by qPCR 4 variants

    Ref.: S-202313820|Turnaround time (TAT) 10 days

  • Pharmacogenetics TYMS genotyping 1 variant

    Ref.: S-202110298|Turnaround time (TAT) 10 days

  • Pharmacogenetics UGT1A1 genotyping (Sanger)

    Ref.: S-202210996|Turnaround time (TAT) 10 days

  • Pharmacogenetics UGT1A1 genotyping (Expansions)

    Ref.: S-202212834|Turnaround time (TAT) 10 days

Other services

TAT (turnaround time): 35 days

Individual gene sequencing and interpretation service. Depending on its size and on the regions of interest, we can offer an approach based on Sanger sequencing or on NGS (enrichment using amplicons or hybridization probes). The NGS-based approach allows detecting copy number variations (CNVs).

TAT (turnaround time): 35 days

Semiquantitative technique that is widely applied in molecular genetic laboratories and that allows diagnosing pathologies caused by copy number variations and, in some cases, by alterations in DNA methylation. A wide variety of commercial kits are available to test individual genes, gene panels related to specific pathologies, or large chromosomal regions involved in microdeletion/microduplication syndromes. HIC offers MLPA services based on MRC-Holland kits.

Luis Ramudo

Head of the area of Pharmacogenetics

Informed consent form Steps to follow Need counseling?
Steps to follow

How to order

1. Download & fill out

Please cover as many fields as possible in both documents

2. Sample collection

Three sample types: saliva, peripheral blood or genomic DNA

3. Pack the sample

Please pack the sample in a way to prevent leakage

4. Send the sample & the request

Please schedule the delivery for Monday–Friday: 8am – 5pm

5. Result: the report

Via: e-mail and/or through the customer portal

Ask us for more information on our Pharmacogenetics services

"*" indicates required fields

Consentimiento*
This field is for validation purposes and should be left unchanged.
Pharmacogenetics Global – 30 genes

ABCC3, ABCG2, CACNA1S, CALU, COMT, CYP1A2, CYP2B6, CYP2C18, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, DPYD, F5, G6PD, GGCX, HLA-A, HLA-B, IFNL4, NAT1, NAT2, NUDT15, RYR1, SLC28A3, SLCO1B1, TPMT, UGT1A1, VKORC1

Clozapine Pharmacogenetics – 10 genes

ACKR1, CYP1A2, CYP3A4, CYP3A5, HLA-B, HLA-DQB1, HTR2A, HTR3A, NFIB, SLCO1B3

Pharmacogenetics of lipid-lowering agents – 6 genes

ABCG2, CYP2C9, SLCO1B1, CYP1D6, CYP3A4, CYP3A5

Antiplatelet and anticoagulation pharmacogenetics – 13 genes

ABCB1, CALU, CES1, CYP2C9, CYP2C18, CYP2C19, CYP4F2, GGCX, GP1BA, HLA-DPB1, LTC4S, PTGS1, VKORC1

Dihydropyrimidine dehydrogenase deficiency (5-fluorouracil toxicity). Sequencing of DPYD gene – 1 gene

DPYD